Therapeutic agent comprising (+)-sibutramine
AssigneeAbbott GmbH & Co. KG
InventorsSharon C. Cheetham, David John Heal
Life of this patent
Estimating the term…
Abstract
The use of (+)-sibutramine in the treatment of depression, obesity, Parkinson's disease, cerebral function disorders and diabetes is described.
Claims29
A method of treating depression in a human which comprises administering to a human in need of antidepressant therapy, an amount of (+)-sibutramine, or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, said amount being sufficient to alleviate depression.
A method for treating obesity or weight gain in a human which comprises administering to a human in need of a reduction in weight, an amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially fie of its (−)stereoisomer, said amount being sufficient to alleviate obesity or weight gain.
A method of treating disorders ameliorated by inhibition of neuronal monoamine reuptake in a human which comprises administering to a human in need of such treatment an amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, said amount being sufficient to alleviate said disorders.
Dependencies are inferred from the claim text.